NCT05565014 - Safety and Efficacy Study of Virus Activated Killer Immune Cells (VAK) for Malignant Pleural and Peritoneal Effusion | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 24, 2020

Primary Completion Date

December 31, 2023

Study Completion Date

June 30, 2024

Conditions

Malignant Pleural EffusionMalignant Peritoneal Effusion

Interventions

DRUG

Virus Activated Killer immune Cells

The VAK made from Pleural Effusion should be given to treat Malignant Pleural Effusion.The VAK made from Peritoneal Effusion should be given to treat Malignant Peritoneal Effusion.

DRUG

Saline

The use of saline was the same as VAK group.

Trial Locations (1)

430079

RECRUITING

Hubei Cancer Hospital, Wuhan